Mallinckrodt (MNK) Receives a Hold from Mizuho Securities

In a report released yesterday, Irina Rivkind Koffler from Mizuho Securities maintained a Hold rating on Mallinckrodt (MNK), with a price target of $13. The company’s shares closed yesterday at $8.32, close to its 52-week low of $8.11.

According to TipRanks.com, Koffler has 0 stars on 0-5 star ranking scale with an average return of -5.3% and a 36.4% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Assertio Therapeutics Inc.

Mallinckrodt has an analyst consensus of Hold, with a price target consensus of $14.92.

See today’s analyst top recommended stocks >>

Based on Mallinckrodt’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $155 million. In comparison, last year the company had a net profit of $15.6 million.

Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MNK in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines.